3 - 4 October 2019

4th Annual MarketsandMarkets Epigenetics Congress

Radisson Blu Edwardian, Grafton Hotel, London
25+
Speakers
120+
Attendees
10
Networking Hours
5+
Sessions

While most of the molecular studies focus over mutational analysis, epigenetics-is the only science which is gaining momentum with its cheaper and faster technology, by making its way to the clinic. Moving on the path of clinical epigenetics, this congress will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.

users

Learn from academia and industry experts about clinical epigenetics, discussing solutions to challenges like drug discovery, identification of molecular inhibitors, gene modification and analysis.

users

Our expert speaker panel will address emergence of novel drugs and next-generation diagnostic technologies with respect to huge growth, government funding for epigenetics research. The congress will host effective mix of case studies, panel discussion and presentations on development of epigenetics, translational epigenetics, clinical epigenetics and more.

users

Engage with pioneers and leaders from academia and industry and stay updated with the latest advancement in epigenetics research right from drug discovery to identification of molecular inhibitors to gene modifications and analysis.

WHAT TO EXPECT
Key Highlights

Epigenetic modification | Genomic profiling | Transcriptional mechanism | Molecular inhibitors | Epigenetic modulators | Clinical applications of epigenetics

Attendee Profiles

Heads, Directors, Group Leaders, Professors, Lecturers, Research Associates, Scientists, Investigators, Fellows, Readers from Pharmaceutical, Bio-pharmaceutical and Research Institutes

Experts & Leaders

Epigenetics | Developmental Epigenetics | Epidemiology | Molecular Biology | Developmental Biology | Biological Sciences | Biochemistry | Medicinal Chemistry | Pharmaceutical chemistry 

CONFERENCE AGENDA
CLINICAL EPIGENETICS
CONFERENCE SPEAKERS
Advisors
Prof. Frank Dekker

Prof. Frank Dekker

Professor, Medicinal Chemistry, Chemical Biology
University of Groningen, Netherlands

Prof. Frank Dekker

Professor, Medicinal Chemistry, Chemical Biology
University of Groningen, Netherlands
Rene Bartz

Rene Bartz

Manager, Development Products
4SC, Germany

Rene Bartz

Manager, Development Products
4SC, Germany
Speakers
Shailendra Singh (Shelly)

Shailendra Singh (Shelly)

Chief Operating Officer
MarketsandMarkets

Shailendra Singh (Shelly)

Chief Operating Officer
MarketsandMarkets
Prof. Frank Dekker

Prof. Frank Dekker

Professor, Medicinal Chemistry, Chemical Biology
University of Groningen, Netherlands

Prof. Frank Dekker

Professor, Medicinal Chemistry, Chemical Biology
University of Groningen, Netherlands
Rémi Terranova

Rémi Terranova

Principle Investigator, Preclinical safety
Novartis Institutes for BioMedical Research, Switz

Rémi Terranova

Principle Investigator, Preclinical safety
Novartis Institutes for BioMedical Research, Switz
Rene Bartz

Rene Bartz

Manager, Development Products
4SC, Germany

Rene Bartz

Manager, Development Products
4SC, Germany
Inma Rioja

Inma Rioja

Senior Director & Portfolio Research Lead at Epige
GSK

Inma Rioja

Senior Director & Portfolio Research Lead at Epige
GSK
Ronan Murphy

Ronan Murphy

Assciate Editor, Clinical Epigenetics
Dublin City University

Ronan Murphy

Assciate Editor, Clinical Epigenetics
Dublin City University
Saulius Klimasauskas

Saulius Klimasauskas

Director and Distinguished Professor, Institute of Biotechnology
Vilnius University

Saulius Klimasauskas

Director and Distinguished Professor, Institute of Biotechnology
Vilnius University
Alfredo Budillon

Alfredo Budillon

Chief Experimental Pharmacology Unit Department of
Istituto Nazionale tumori G. Pascale

Alfredo Budillon

Chief Experimental Pharmacology Unit Department of
Istituto Nazionale tumori G. Pascale
SPONSORS
Sponsors & Exhibitors
example-image

Covaris, Inc.

example-image

Diagenode

example-image

Resverlogix Corp.

example-image

Lonza

example-image

GenomeScan

example-image

Abcam

Visiting Partners
example-image

EpiCypher

PARTNERS
Supporting Association
MediWales

MediWales

BioPartner UK

BioPartner UK

EuropaBio

EuropaBio

Epigenetics Society

Epigenetics Society

BioAlps

BioAlps

Media Partners
example-image

CrowdReviews.com

example-image

Medical events guide

example-image

Technology Networks

example-image

GEN

example-image

Bentham Science

example-image

SciDoc Publishers

example-image

PharmaTutor

example-image

PharmaVOICE

example-image

Biocompare

LOCATION
Radisson Blu Edwardian, Grafton Hotel, London
  • Radisson Blu Edwardian, Grafton 1
  • Radisson Blu Edwardian, Grafton
    About the Hotel

    Radisson Blu Edwardian Hotels is a collection of luxury hotels in central London, Heathrow and Manchester. The Edwardian experience is about a new kind of luxury which makes you feel immediately comfortable and never intimidated. 

    For any queries regarding the hotel booking please write to us at events@marketsandmarkets.com

    Hotel Booking Link

    You will receive a link to book your accommodation via email once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on events@marketsandmarkets.com

    NEWS
    Card image cap

    About five months ago Passage Bio that basically produces gene therapies for not so common monogenic CNS disease, in partnership with Catalent's paragon launched a unit that is devoted to manufacturing suite Paragon Harman's, MD, facility. The other cGMP suite whose worth is not being revealed yet is expected to hit it's functional phase from mid-2020 and is support Passage Bio's supply requirements from clinical through commercial phases. Read more....

    Card image cap

    Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). Read more...

    Card image cap

    A new treatment for a rare childhood disorder which cost $2.125 million for a single dose, one of the most expensive medicine available is approved by The US Food and Drug Administration. Read more....

    PAST EVENT GALLERY